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Abstract
Over recent decades, gene therapy, which has enabled the treatment of several incurable
diseases, has undergone a veritable revolution. Cell therapy has also seenmajor advances
in the treatment of various diseases, particularly through the use of adult stem cells
(ASCs). The combination of gene and cell therapy (GCT) has opened up new opportuni-
ties to improve advanced therapy medicinal products for the treatment of several dis-
eases. Despite the considerable potential of GCT, the use of retroviral vectors has major
limitations with regard to oncogene transactivation and the lack of physiological expres-
sion. Recently, gene therapists have focused on genome editing (GE) technologies as an
alternative strategy. In this review, we discuss the potential benefits of using GE technol-
ogies to improve GCT approaches based on ASCs. Wewill begin with a brief summary of
different GE platforms and techniques andwill then focus on key therapeutic approaches
that have been successfully used to treat diseases in animal models. Finally, we discuss
whether ASC GE could become a real alternative to retroviral vectors in a GCT setting.
K E YWORD S
adult stem cells, CRISPR, electroporation, gene delivery systems in vivo or in vitro, gene
therapy, hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), pluripotent
hemopoietic stem cells
Karim Benabdellah and Francisco Martin are senior authors.
Received: 10 October 2019 Accepted: 10 January 2020
DOI: 10.1002/sctm.19-0338
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
674 STEM CELLS Transl Med. 2020;9:674–685.wileyonlinelibrary.com/journal/sct3
1 | REASONS FOR USING ADULT STEM
CELLS
Gene and cell therapy (GCT) strategies utilize multiple cell types for
the treatment of different diseases.1 The most common approaches
use adult stem cells (ASCs), also known as somatic stem cells, as well
as T cells. However, other differentiated cell types, such as B, NK and
macrophage cells, as well as pluripotent stem cells (PSCs), have also
been used.2,3 In particular, PSCs, which are essentially embryonic stem
cells (ESCs), and induced PSCs (iPSCs), have been proposed as potent
therapeutic tools due to their ability to produce all types of mature
cells in the human body. However, although PSCs are widely used in
basic research, very few studies have been carried out on their clinical
applications. PSCs are restricted to a small number of applications in
clinical trials according to recent data published on the U.S. National
Institute of Health's web page regarding clinical trials (https://
clinicaltrials.gov). The possibility of PSC-derived products being con-
taminated by potentially tumorigenic undifferentiated cells, as well as
the lack of clear regulatory guidelines, has delayed their clinical appli-
cation. In addition, genetic alterations can be accumulated during PSC
passage and/or differentiation.4,5 Of the 25 clinical studies using
PSCs, 21 use hESCs, 4 are based on iPSCs, while none use genetically
modified PSCs.
Unlike PSCs, multipotent, undifferentiated ASCs, which are found
in all organs of living organisms, are involved in physiological tissue
regeneration.6 ASCs, which have a self-renewal capacity, can give rise
to some or all of the differentiated cells of the tissue in which they
reside. They have been widely used in clinic due to their ability to
regenerate tissues, such as blood and skin, and to dampen immune
responses. Most ASCs used in clinical trials are hematopoietic progen-
itor stem cells (HPSCs) and mesenchymal stem cells (MSCs), with over
3000 clinical trials carried out so far (ClinicalTrials.gov 2019). A major
reason for the success of ASC transplants is their safety. However, in
several applications, genetic modification of ASCs is necessary in
order to achieve the desired therapeutic benefits.1 Genetically modi-
fied ASCs have been successfully employed in the treatment of sev-
eral disorders through the use of integrative viral vectors.7 These
ASCs include HSPCs which are chosen due to their capacity to be
grafted in bone marrow and give rise to all hematopoietic lineages.
Over 120 clinical trials involving genetically modified HSPCs are on-
going or have been completed worldwide, 7 of which are now in
Phase III or IV, with one medicinal treatment (Strimvelis) already
approved by the Food and Drug Administration (FDA) and European
Medicines agency (EMA). In addition to HSPCs, other gene-modified
ASCs have also reached Phase I/II clinical trials, including MSCs,
T stem cell memory (TSCM) cells, epidermal stem cells (EpSCs), endo-
thelial stem cells (EnSCs), and neural stem cells (NSCs) (data obtained
from https://clinicaltrials.gov and http://www.abedia.com/wiley/).
Most of the clinical trials mentioned above rely on semi-random inte-
gration of one or more copies of the therapeutic gene introduced into
the host genome using γ-retroviral or lentiviral vectors. However, this
type of genetic integration has generated concerns regarding the pos-
sibility of cellular transformation and expression variability.8 In this
review, we discuss the potential role of genome editing
(GE) technologies in overcoming the limitations of retroviral vectors.
We will focus on ex vivo strategies using ASC GE in clinical and/or
preclinical settings.
2 | GE STRATEGIES
GE involves a group of technologies that enable the cellular genome to
be modified. However, for its successful in-clinic application, GE needs
to be used efficiently either in vitro or in vivo without affecting the nor-
mal physiology of targeted human cells. Nuclease-independent9,10 tech-
nologies, as well as those based on the use of specific endonucleases
(SENs), are used to carry out GE.11 The nuclease-independent strategy
facilitates GE without generating double strand breaks (DSBs) by using
systems that improve homologous directed recombination (HDR) such
as adeno-associated virus (AAV) vectors10 or that introduce distortions
in the target DNA that triggers repair mechanisms, such as triplex-
forming oligonucleotides (TFOs)9 (Figure 1).
Whether GE systems generate DNA breaks or distortions, the tar-
get cell triggers different DNA repair mechanisms, mainly through
non-homologous end joining (NHEJ) or homology-directed repair
(HDR). NHEJ is a type of double-stranded break repair mechanism
that does not require a DNA donor. The targeted sequences are rap-
idly processed by cellular machinery which generates small insertions
or deletions (indels). Although a less efficient DNA repair mechanism,
HDR is more precise than NHEJ. When a compatible donor DNA tem-
plate is delivered to the cell, these DNA molecules are incorporated
into the endogenous locus, thus enabling precise modifications to be
carried out (Figure 2). The most advanced strategy in terms of preclini-
cal and clinical applications is NHEJ-mediated GE which is highly effi-
cient. NHEJ-based GE strategies using SENs and ASCs have already
reached the clinical stage for the treatment of sickle cell disease
(SCD), B-thalassemia, AIDS, and acute lymphoblastic leukemia.
There are four main types of SEN: mega nucleases (MGNs), tran-
scription activator-like effectors nucleases (TALENs), zinc finger
Significance statement
Recent advances in adult stem cells and genome editing tech-
niques have enabled scientists to envisage the generation of
efficient and safe advanced therapy medicinal products for the
treatment of untreatable diseases. Hematopoietic progenitor
stem cells are now clearly regarded as the cell type of refer-
ence. Promising results have been achieved in controlling AIDS
and hemoglobinopathies, resulting in several clinical trials.
Promising results have also been obtained in the treatment of
monogenic diseases, including X-SCID, SCID-ADA, X-CGD, and
Fanconi anemia, indicating that further clinical trials will be
approved in the near future.
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nucleases (ZFNs), and clustered regularly interspaced short palin-
dromic repeat (CRISPR)/CRISPR-associated system 9 (CRISPR-Cas9)
systems.11 The success of GE approaches greatly depends on the type
of gene editing tools used and on how these tools are delivered to the
cells and tissues. Another important feature is safety, which can be
measured by the levels of unwanted off-target modifications outside
the target locus. As both NHEJ and HDR strategies are capable of
introducing undesirable modifications into the host genome, it is cru-
cial to accurately determine the safest system to be used
(a combination of the appropriate GE tool, delivery system, and
strategy).12–16
In order to obtain GE-ASCs, cells must first be isolated from their
original tissue and then edited ex vivo. As explained above, how GE
tools (SENs and/or donor) are delivered to the ASCs is crucial for the
success of the strategy. These delivery methods can be viral,16–19
nonviral,20–22 or a combination of both,13 and should be transient,
highly efficient, and nontoxic. Recently, a hybrid method based on
murine leukemia virus particles has produced interesting results.23,24
A more detailed review of delivery systems for GE can be found
elsewhere.25
The most effective platforms for NHEJ-GE of ASCs are mRNA
nucleofections for ZFNs and the ribonucleoprotein complex for
CRISPR. Nucleofection, a type of electroporation system, is probably
the most successful physical non-viral-based method for delivering
macromolecules to target cell nuclei. It is important to note that
nucleofection produces a spike in SEN expression, thus reducing tox-
icity and increasing GE specificity.7,26 Clinical-grade electroporators,
which can be used in clinical trials for the treatment of AIDS and
blood disorders, have been developed. In addition to nucleofection,
adenoviral (AdV), AAV, and integration-deficient lentiviral vectors
(IDLVs)16,27 are often used in HDR-GE strategies. Although capable of
efficiently delivering large donor DNAs, these viral vectors can also be
used to deliver specific nucleases.
A major concern with using GE technologies as a treatment
option arises from the possibility of introducing off-target unwanted
alterations into the modified genome.12,28 However, none of the
methods for detecting the distribution and frequency of off-targets
introduced by SENs are regarded as sufficiently robust to be
implemented in clinical trials.14 Nevertheless, it is very useful to com-
pare different off-target SEN activities in order to develop more effec-
tive and safer strategies. Some research groups have focused on
CRISPR-based systems which have no endonuclease activity but
maintain the capacity to bind to the site indicated by the gRNA. New
CRISPR/Cas9, such as cytosine base editors and adenine base
editors,29,30 have been developed. These editors combine a catalyti-
cally dead Cas9 (dCas9) with a cytosine or adenosine deaminase
domain in order to facilitate direct single-base pair substitutions (C:G
to T:A and A:T to G:C) without generating DSBs. More recently, the
group led by Dr. Liu has developed “prime editing” technology by
combining a dCas9, a reverse transcriptase and a prime editing guide
RNA (pegRNA). This technique enables DNA to be edited with
unprecedented precision, with fewer errors being introduced than
previous gene-editing technologies.31
Although technical issues still need to be addressed, 23 GE clini-
cal trials using ZFNs (14 clinical trials), CRISPR/Cas9 (16 clinical tri-
als), and TALENs (3 clinical trials) for the treatment of infectious
F IGURE 1 Current genome editing technology platforms can be divided into two main groups: specific endonuclease (SEN)-based (right) and
nuclease-independent (left) platforms. The three main types of SEN-based genome editing platforms are the transcription activator-like effector
nuclease (TALEN), zinc finger nuclease (ZFN), and clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein
9 (Cas9) systems. The principal SEN-free gene editing platforms use recombinant adeno-associated virus (rAAV) vectors and triplex-forming
oligonucleotides (TFOs)
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diseases (HIV-1 and HPV), cancer, as well as blood and metabolic dis-
orders, are currently on-going (Clinicaltrials.gov Dec 2019). Six of
these clinical trials use ex vivo ASC techniques to treat AIDS and
blood disorders.
3 | GE of ASCs
As mentioned above, the vast majority of clinical trials involving gene-
edited stem cells use ASCs. Although those using HPSCs are by far
the most successful,1 EpSCs, MSCs, TSCM cells, and NSCs have also
produced promising results.
3.1 | Genome-edited HSPCs
The engraftment of HSPCs in a recipient's bone marrow, which gives
rise to all types of hematopoietic cells, provides a wide range of inter-
vention opportunities for a large number of disorders.7 Despite being
some of the most desirable target cells for stem cell-based therapies,
HSPCs are highly resistant to gene modification and preferentially use
NHEJ rather than HR pathways to repair damage to DNA.11 This pref-
erence explains why the vast majority of HSPC GE studies and clinical
trials use NHEJ-based strategies rather than HR-based approaches
(Figure 3). Table 1 summarizes important preclinical studies of HSPC
gene therapies (GTs).
F IGURE 2 Genome editing strategies based on the activity of specific nucleases (SENs). Once SENs generate a double strand break in the
target locus (top), the cell triggers two main repair pathways depending on the availability of homologous DNA and cell type. Non-homologous
end joining (NHEJ, left) preferentially occurs on G1 phase and quiescence cells, whereas homologous recombination (HR, right) generally requires
cell division and takes place in the S phase of the cell cycle. In the NHEJ pathway, the donor or template DNA are not available and, after SEN
cleavage, the binding of the proteins Ku70-Ku80 protects the DNA ends against excessive resection and promotes DNA repair by recruiting the
Artemis, DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and DNA ligase IV complex. This repair pathway introduces short DNA
insertions or deletions (indels) into the target site and facilitates different GE approaches: (a) generation of knockout genes by eliminating the
ATG or by changing the open reading frame, thus generating premature stop codons, (b) repair of the correct open reading frame on mutated
genes, or (c) elimination/alteration of enhancers/promoter regions. In contrast to NHEJ, in the HR pathway, the cell uses a donor DNA to fix DNA
breaks introduced by SENs. HR repair is initiated by the combined action of the MRE11-RAD50-NBS1 (MRN) complex and RBBP8 generating
single strand DNA where replication protein A (RPA), in association with Rad and BRC proteins bind and promote HR by invading the
homologous template. By providing abundant homologous DNA donors, the HR pathway can also be used for different GE strategies: (a) insertion
of a cDNA sequence under the regulation of a specific locus in order to provide locus-specific, physiological expression of the particular cDNA.
(b) Insertion of an expression cassette (promoter and cDNA) into a safe location (harbor). (c) Alternatively, HR can be used for HR-directed repair
(HRDR) of disease-causing mutations (precise gene editing) by providing DNA donor harboring the corrected DNA sequences
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3.1.1 | HSPC GT for infectious diseases (HIV-1)
Although several strategies based on GE technology have been designed
to fight different infectious agents, only human immunodeficiency virus
type I (HIV-1) has been targeted using HSPC GE. Initial studies have
demonstrated that long-term HSCP-CCR5-KO repopulation can be
achieved using ZFN43,44 and CRISPR/CAS942,54 strategies, both of which
provide protection for HIV-1 in humanized NOD/SCID/IL2R gamma
mice. Paterson et al. were the first to use nonhuman primates (NHPs) to
demonstrate multilineage repopulation of genome-edited HSPCs.45
These preclinical studies led to the first two clinical trials to evaluate the
feasibility, safety, and engraftment of allogeneic and autologous HSCP-
CCR5-KO in China (NCT03164135) and the United States
(NCT02500849), respectively (Figure 4). The clinical trial being carried
out in the United States using autologous HSPCs (CCR5-KO) and ZFNs,
for which patients were recruited in September 2019, is sponsored by
the City of Hope Medical Center in collaboration with Sangamo Thera-
peutics. These patients were placed on either a 2- or 3-day course of
busulfan prior to product infusion in order to enhance HSPC engraft-
ment. The clinical trial in China has already produced an initial report on
HIV-1-infected patients treated with genome-edited HSPCs.55 Paterson
et al. treated HIV-infected patients with acute lymphocyte leukemia
(ALL) at the Academy of Military Medical Sciences in China using
CRISPR/CAS9 to edit the CCR5 locus of allogeneic HSPCs. The patients
with ALL achieved complete remission, with CD4+ cells in CCR5KO mice
found to increase following a pause in antiretroviral therapy. However,
the percentage (5%) of CCR5 disrupted was relatively low, indicating the
need for further improvement.
3.1.2 | GE-HPSCs for monogenetic diseases
Monogenetic diseases are a series of inherited pathologies associated
with alterations in a single gene that can be point mutations, indels, or
large deletions. These diseases include hemoglobinopathy, X-linked
severe combined immunodeficiency (X-SCID), and Fanconi anaemia
(FA), which were initially considered to be targets for treatment with
gene-corrected HPSCs.
Hemoglobinopathies
Hemoglobinopathies, characterized by defective hemoglobin synthesis,
include SCD, and β-thalassemia. Lentiviral vector (LV)-based GT has
been highly successful in integrating the normal β-globin gene into
HPSCs, a strategy which has reached clinical trial phase III using
F IGURE 3 Diagram showing potential clinical HPSCs genome editing applications using either NHEJ- or HR-based approaches (blue and red
arrows, respectively). The target conditions are indicated in gray boxes, and each arrow points to the locus targeted in each case
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LentiGlobin (NCT03207009). Despite their considerable success, LVs,
which are integrated into the transcriptionally active locus, represent a
potential risk of cellular transformation.8 GE appears to be a potentially
safer alternative for restoring normal β-globin expression either through
insertion of the healthy β-globin gene via the HR pathway or through
reactivation of the fetal γ-globin gene34–38,56–58 (Figure 5). The most
successful strategies are aimed at reactivating fetal γ-globin gene
expression by disrupting the negative regulatory region of the γ-globin
gene.59, 60 These were the first human GE strategies to be investigated
in clinical trials using CRISPR/CAS9 (CTX001, NCT03745287) and later
ZFNs (ST-400; NCT03432364) for the treatment of β-thalassemia and
SCD. New clinical trials have been approved for these diseases using
CRISPR (iHSCs; NCT03728322) and ZFNs (PRECIZN-1;
NCT03653247). Recently, CRISPR Therapeutics and Vertex published
the initial results of monitoring the CTX001 trial at month 9 for a patient
with β-thalasemia and at month 4 for a patient with SCD (www.crisprtx.
com). The β-thalasemia patient in the transfusion-independent clinical
trial had total hemoglobin levels of 11.9 g/dL, fetal hemoglobin of
10.1 g/dL, and erythrocyte-expressing fetal hemoglobin of 99.8%, with
no severe side effects. The SCD patient also underwent significant
TABLE 1 Examples of successful preclinical studies, combining different type of ASCs and genome editing tools, for the treatment of
different genetic and infectious diseases
Cells type Diseases GE strategies Tools Ref
Hematopoietic progenitor stem cells Primary immune deficiency HR - insertion in safe harbor
HR - insertion in affected locus
CRISPR-Cas9/ZFNs 32, 33
ZFNs 27
Hematoglobinopathies HR - gene repair CRISPR-Cas9 34
ZFNs 35
NHEJ - therapeutic mutation TALENs 36
CRISPR-Cas9 37
ZFNs 38
Fanconi anemia HR - insertion - safe harbor ZFNs 39
Cancer HR - therapeutic mutation
NHEJ - exon deletion
CRISPR-Cas9 40, 41
Infectious diseases NHEJ - gene disruption CRISPR-Cas9 42
ZFNs 43–45
Other stem cells
Mesenchymal stem cells Liver fibrosis HR - insertion in safe harbor TALENs 46
Parkinson's disease 47
Epidermal stem cells Dystrophic epidermolysis bullosa NHEJ - therapeutic mutation CRISPR-Cas9 48, 49
TALENs 50
Junctional epidermolysis bullosa HR - insertion in affected locus CRISPR-Cas9 51
Neural stem cells Krabbe disease HR - insertion in safe harbour CRISPR-Cas9/TALENs 52
Muscle stem cells Duchenne muscular dystrophy HR - gene repair CRISPR-Cas9 53
F IGURE 4 Diagram showing the
principal steps in a clinical trial using
autologous as compared to allogenic
HSPCs. HPSCs were harvested from
patients and healthy donors and
cultivated in vitro. Once an optimal
number of cells with the appropriate
phenotype were obtained, they were
subjected to gene editing and then
infused back into the patient who was
treated with the appropriate conditioning
regimen
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improvement, with the occurrence of novaso-occlusive crisis (VOC) epi-
sodes (total hemoglobin levels of 11.3 g/dL and 94.7% of erythrocytes
expressing fetal hemoglobin).
Fanconi anemia (FA)
FA, characterized by congenital malformation and cancer susceptibil-
ity, with defective repair of DNA inter-strand crosslinks (ICLs), is a rare
disease associated with genetic mutations in one or more of the
22 FANC genes. FA is an excellent target for genetic correction, as
corrected stem cells and their progeny have a strong selective in vivo
advantage.61 Five on-going GT trials, including one at the phase II
stage (NCT02931071), are investigating the efficacy and safety of
HSPCs expressing the correct version of the FANCA gene through
the use of LVs (ClinicalTrials.gov Sept 2019). Despite the positive out-
come of the latest clinical trial using LVs,61 GE is also being studied as
a potential alternative to FA GT. However, the intrinsic problems of
repairing ICL lesions in the cells of FA patients have made gene ther-
apists cautious about using gene editing to treat these patients. Nev-
ertheless, several studies have demonstrated the feasibility of the GE
of fibroblasts from FA patients harboring mutations.62 Diez et al.,
who have demonstrated the feasibility of phenotypic correction of
FA HPSCs by inserting a FANCA donor in an AAVS1 locus via HR,
have also shown that GE can be effective in HPSCs when ZFNs are
used.39
Primary immunodeficiencies (PIDs)
Several PIDs, including severe combined immune deficiencies
(SCID-X1, SCID-ADA), Wiskott-Aldrich syndrome (WAS), chronic
granulomatous disease (CGD), and X-linked hyper-IgM (X-HIM), have
been successfully treated using GT-based approaches involving both
γ-retroviral and LVs.63 Given the mutagenic nature of first-generation
γ-retrovirus-based vectors, some patients developed leukemia. How-
ever, the latest generation of these vectors has produced better
results, with physiological promoter-driven, self-inactivating γ-retrovi-
rus64 and lentivirus65,66 vectors, in particular, found to be safer and
more effective in clinical settings.1 As a result, a new advanced ther-
apy medicinal product (ATMP), named Strimvelis, has been approved
for the treatment of SCID-ADA, with several others on the way. GE
has opened up the possibility of further improvements in GT strate-
gies by expressing the therapeutic transgene in a more physiological
manner through the use of endogenous regulatory sequences and/or
reductions in genotoxicity caused by semi-random integration of ret-
roviral vectors. Different cell models have been used to test the feasi-
bility of using GE to correct genetic mutations causing PIDs.67
However, HPSC GE is problematic due to poor permissiveness to
gene transfer and limited HD DNA repair pathways in these cells. In
2014, Genovese et al. demonstrated, for the first time, successful cor-
rection of target genes in human HPSCs.27 Using a HR-based
approach based on ZFN mRNA nucleofection and IDLV-DNA donors,
they repaired the mutated IL2RG gene of HPSCs from a patient with
SCID-X1 and successfully engrafted genome-edited HPSCs, giving rise
to functioning hematopoietic cells. In recent years, using gene-editing
tools, other research groups, who have produced new studies on
SCID-X132,33 using AAV6 for donor delivery and ZFN mRNA,32 as
well as CRISPR/Cas9 RNP33 nucleofection, have confirmed the feasi-
bility of correcting HPSCs from different PIDs.32,33,68,69 Kuo et al.
F IGURE 5 NHEJ GE strategies for treating β-thalassemic and sickle cell disease (SCD) patients. Schematic representation of the β-globin
cluster in healthy individuals (top drawing). Only adult globins, δ-globin and β-globin, are expressed in healthy adult individuals. The Bcl11a gene is
expressed thanks to the erythroid-specific enhancer and blocks fetal globin (γG and γA) expression. In β-thalassemia and SCD patients (middle
drawing), mutations in the β-globin gene abrogate its normal expression, preventing the generation of the predominant adult hemoglobin form
(αβ). Three different clinical trials are currently on-going to investigate the feasibility of eliminating the erythroid-specific enhancer of the Bcl11a
gene on HSPCs (Bottom drawing) using ZFNs (NCT03432364 and NCT03745287) or CRISPR/Cas9 (NCT03653247). By disrupting Bcl11a gene
expression in erythroid cells, the fetal γ-globin will be expressed in adults forming fetal hemoglobin (αγ) which should restore normal function
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have shown that AAV6 harboring the donor DNA could also be com-
bined with TALEN mRNA or CRISPR/Cas9 RNP to restore X-linked
hyper-IgM syndrome.68 Using a different platform (Cas9 mRNA, gRNA
and ssODN), De Ravin et al.69 repaired up to 20% of HSPCs from
patients with X-linked chronic granulomatous disease (X-CGD). See
Table 1 for further information on GE for PID.
HLA gene editing enables the generation of HSPC universal donor
cells
In recent decades, unmodified allogeneic HLA-matched HSPCs have
been used to treat malignant and non-malignant blood disorders.
However, the success of transplants depends on the existence of
compatible donors, whereas the risk of graft rejection is still a major
concern. A definitive approach could be developed through the
genetic elimination of HLA mediated by GE. Torikai et al. have used
ZFNs to fully disrupt HLA-A in T cells.70 Recognition of GE-T cells by
natural killers was circumvented by the expression of non-classical
HLA molecules. This research group later demonstrated the feasibility
of their approach with HSCs which maintains the engraftment of the
engineered cells and reconstitutes hematopoiesis in immunocompro-
mised mice.71 Other strategies could benefit from using universal
HLA−HSPCs as ATMP cells by, for example, enabling the manufacture
of erythrocytes and/or platelets from universal HLA−HSPCs.
3.1.3 | HSPC GE for cancer GT
Genetically modified T cells expressing a chimeric antigen receptor
(CAR) are a powerful new class of advanced therapy medicinal prod-
uct.72 CD19-targeting CAR-T cells were recently approved by the FDA
for the treatment of refractory type B leukemia and lymphomas. This
approach does not discriminate between normal and malignant B cells,
although patients can live almost normal lives without B cells if treated
with immunoglobulins. CD33 is an interesting target for acute myeloid
leukemia (AML).73 Unfortunately, CD33 is expressed in both malignant
and in normal myeloid cells (including progenitors), which are destroyed
by CD33-CAR-T cells. In order to overcome this limitation, several
research groups have targeted CD33 from normal HSPCs using
CRISPR/Cas9 in order to generate functional myeloid cells resistant to
CAR-T αCD33.40,41,74 Gene-edited HSPCs showed normal myeloid
function and resistance to CD33 therapy mediated by T cells engineered
to express CAR-targeting CD33.40,41,74 It is important to note that
multilineage reconstitution has been demonstrated in both mouse and
NHP models.40,41,74
3.2 | Other stem cells
GE of other types of cells, such as EpSCs, MSCs, as well as muscle and
neural stem cells, has also produced interesting results in the treat-
ment of several diseases. However, except for EpSCs, the results have
been insufficiently conclusive to test these strategies in clinical trials.
The most important studies in the field are summarized below.
3.2.1 | Epidermal stem cells
The genetic modification of EpSCs has important applications in the treat-
ment of diseases such as recessive dystrophic epidermolysis bullosa
(RDEB) and junctional epidermolysis bullosa (JEB). Major advances have
beenmade using gamma-retroviral and LV vectors to generate autologous
artificial skin expressing Col7a1 for RDEB and LAMB3 for JEB; JEB can be
genetically corrected by transplanting genetically modified EpSCs.75,76 As
discussed above, EPSC GE could be a good alternative to retroviral vec-
tors, as several research groups have managed to restore Col7Aa148–50
and LAMB351 expression by genetically editing EpSCs from RDEB and
JEB patients, respectively. In both these pathologies, artificial skin gener-
ated using genetically modified EpSCs has enabled long-term engraftment
of phenotypically normal skin. This provides strong support for future
ex vivoGE clinical trials for the treatment of RDEB and JEB patients.
3.2.2 | Mesenchymal stem cells
Due to their regenerative potential and anti-inflammatory properties,
MSCs have been widely used in clinical trials for multiple diseases.
However, despite the major successes of MSCs in some disorders,
which have led to the approval of MSC therapies,77–79 they have had
limited therapeutic benefits in other applications. To overcome these
limitations, several research groups are investigating the feasibility of
genetically modifying MSCs to express different genes that enhance
their therapeutic efficacy.80 As previously described with respect to
other cell types, GE has also become an alternative to GT vectors.
GE-MSCs, which are being studied as a platform for the delivery of
proteins into the blood stream,81 are an interesting tool in the treat-
ment of blood disorders caused by the absence of plasma proteins. In
this setting, GE has been used to insert hFIX and hFVIII into the
AAVS1 locus of MSCs through homologous recombination (HR) in
order to treat hemophilia A and B.82,83 GE-MSCS are also considered
a potential alternative treatment for neurodegenerative diseases such
as Parkinson's disease (PD). Using this approach, MSCs have been
engineered to secrete soluble receptors of advanced glycation end
products from AAVS1 loci.47 The aim is to reduce advanced glycation
end product concentrations involved in PD and Alzheimer's disease.
GE-MSCs have also been used in the treatment of ischemia in an ani-
mal infarct model. Meng et al. have used TALENs to integrate the
IL-10 gene into the AAVS1 safe harbor locus of MSCs and have per-
formed an intra-myocardial transplant in the infracted myocardium,
which reduced pro-inflammatory factor expression and increased vas-
cular density.84,85 The same approach was used to ameliorate liver
fibrosis.46 All these data indicate that GE is becoming a real alternative
to viral and nonviral vectors in generating genetically modified MSCs.
3.2.3 | Neural stem cells
Neural stem cells (NSCs), whose regenerative capacity, as with MSCs,
can be improved by GE, have promising, although not immediate,
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clinical potential as a cellular treatment for neurological diseases.
Recently, Dever et al. demonstrated that NSCs can be modified genet-
ically at multiple loci using Cas9 mRNA and DNA donors. They
showed that, upon transplantation, GE-NSCs can migrate and differ-
entiate into astrocytes, neurons and myelin-producing oligodendro-
cytes. They also highlighted the therapeutic potential of GE-NSCs by
generating NSCs overexpressing the GALC enzyme which can cross-
correct the GALC enzyme activity of fibroblasts obtained from Krabbe
disease patients.52 These findings highlight the therapeutic potential
of GE-NSCs, not only for the regeneration of neural cells but also as a
Trojan horse to deliver proteins to the central nervous system.
3.2.4 | Muscle stem cells
Muscle stem cells are undifferentiated cells capable of producing new
muscle tissue and of fusing with pre-existing myofibers in order to
repair damaged myofibers. Muscle satellite cells (MuSCs) are probably
the most studied muscle stem cells, a population of cells that are capa-
ble of self-renewal and differentiation into muscle fibers which repre-
sent an ideal target for therapeutic GE.86 Zhu et al. have developed a
fibrin gel culture system to selectively expand MuSCs from an mdx
mouse model for Duchenne muscular dystrophy (DMD) research. These
cells were successfully corrected using CRISP/Cas9-based GE and,
following transplantation to mdx mice, restored dystrophin expression
in skeletal muscle.53 This demonstrates the feasibility of using ex vivo
GE-MuSCs to target and correct DMD.
3.2.5 | T stem cell memory cells
TSCM cells, which constitute a recently described 2% to 3% circulat-
ing T-cell subpopulation,87 have a naive T-cell phenotype, express a
CD62L memory marker, proliferate, self-renew, and generate effec-
tor/memory T cells. TSCM cells have emerged as a highly interesting
population for adoptive T-cell therapies for cancer88 and inherited
immunodeficiency.89 As with other ASCs, GE has also been applied to
TSCM cells to enhance the potency of CAR T cells for the treatment
of hematological malignancies and solid tumors. Eyquem et al.90
inserted a α-CD19 CAR into the T-cell receptor A constant (TRAC)
locus using Cas9 mRNA and gRNA electroporation followed by trans-
duction with AAV6 harboring the donor DNA containing the CAR.
This strategy generated off-the-shelf CAR-T cells (without TCR) which
expressed the CAR physiologically through the endogenous TCR pro-
moter. This approach has also been used to improve efficiency thanks
to the maintenance of the TSCM phenotype following repeated expo-
sure to the antigen. Recently Sachdeva et al. used a similar approach,
involving TALENs instead of CRISPR/Cas9, to insert CAR cDNAs into
the TRAC locus and to insert the proinflammatory cytokine IL12 into
the CD25 or PD1 loci.91 This resulted in the physiological expression
of the CAR and a transient secretion of IL12 which depends on tumor
engagement (following the expression patterns of CD25 or PD1
locus). In addition, the targeted integration of IL12 at the PD1 locus
inactivated PD1, a major T-cell immune checkpoint, and increased the
cell surface of CD62L, a marker of TSCM cells. This strategy resulted
in increased CAR-T cell cytotoxicity and extended survival of mice
engrafted with solid tumors. A further potential improvement in gen-
erating universal off-the-shelf CAR-T cells involves simultaneously
deleting TCR and beta-2 microglobulin (B2M) genes to reduce graft-
vs-host disease (GVHD) and CAR-T-cell rejection. Recently, Choi
et al.92 generated αEGFRvIII CAR-T cells lacking the expression of the
TCR, B2M, and PD1 electroporating RNP (Cas9 protein and sgRNAs
targeting TRAC, B2M, and PD1 loci) and transducing with AAV6 vec-
tors containing donor DNAs for insertion of the EGFRvIII CAR con-
struct at the different loci. The authors showed increased survival of
mice in mouse models of glioma, which correlated with the increased
presence of CAR-T cells with a TSCM phenotype.92
4 | CONCLUSION
In recent decades, genetic modification of ASCs using traditional GT
vectors has opened up new opportunities to improve ATMPs for the
treatment of several diseases. Most approaches use retroviral vectors
to achieve stable transgene expression in ASCs upon expansion and
differentiation. However, the use of retroviral vectors has several
drawbacks associated with oncogene activation and the lack of physi-
ological transgene expression. Recent advances in GE technologies
have enabled researchers to design next-generation GM-ATMPs
based on ASCs. Using cellular HR- and NHEJ-based repair pathways,
GE achieves precise, and safe ASC genetic modifications such as gene
disruption, addition and repair, as well as the generation of therapeu-
tic mutations. Six ongoing phase I and II clinical trials are currently
being carried out to study the safety and effectiveness of GE-ASCs in
the treatment of AIDS, SCD, and β-thalassemia. The trials are based
on GE-HSPCs and NHEJ disruption of CCR5 for the treatment of
AIDS and on the inactivation of regulatory regions controlling the fetal
γ-globin gene repression for the treatment of SCD and β-thalassemia.
GE-HSPCs have also produced promising results in preclinical models
for monogenetic diseases such as severe X-SCID, SCID-ADA, X-CGD,
and FA, as well as for cancer and transplantation. In addition to
HSPCs, several other ASCs have been studied as GE targets in thera-
peutic applications. GE of EpSCs, MSCs, NPCs, and MuSCs has also
produced interesting results in animal models of RDEB, JEB, hemo-
philia, PD, and Krabbe disease.
5 | FUTURE PERSPECTIVES
It is still too early to speculate whether GE-ASC clinical trials for the
treatment of AIDS, SCD, and β-thalassemia will lead to the approval
of ATMPs for clinical use. For that to happen, these strategies need to
demonstrate improved therapeutic effectiveness as compared to
other GT approaches based on retroviral vectors already in phase III.
Some of these GT techniques are about to be authorized as ATMPs.7
For example, Lentiglobin, a HSPC-LV-based ATMP, has demonstrated
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excellent, long-term therapeutic benefits in β-thalassemia patients,
with no severe secondary effects. Therefore, provided GE-ASC clinical
trials demonstrate a similar level of therapeutic efficiency and reduced
genome alterations as compared to RV-based GT, GE-ASCs will be
approved as ATMPs. Regardless of the results achieved in ongoing
clinical trials, we believe that, in the near future, next-generation
ATMPs will incorporate GE-ASCs in their arsenal. The field of GE is
advancing at an unprecedented pace, with new, more efficient and
safer tools being developed each year. Advances in the specificity and
versatility of SENs,28,93–95 in strategies to improve HR repair96,97 and
in delivery methods13,16,98–100 have been and will remain crucial. In
addition, the field of ASCs is evolving exponentially due to their safety
and potential applications in regenerative medicine.26,101–105 New
developments in both GE and ASCs are bound to provide opportuni-
ties to improve the safety and efficacy of GE-ASCs in order to achieve
the final objective: the approval by official medical authorities of GE-
ASCs as ATMPs.
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